HALOZYME THERAPEUTICS INC Form 8-K January 09, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

001-32335

(Commission

File Number)

Delaware

(State or other jurisdiction of incorporation)

11388 Sorrento Valley Road, San Diego, California

(Address of principal executive offices)

Registrant s telephone number, including area code:

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

88-0488686

(I.R.S. Employer Identification No.)

92121

(Zip Code)

858-794-8889

January 6, 2009

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The employment of Richard C. Yocum ended on January 6, 2009. Dr. Yocum held the title of Vice President, Clinical Development and Medical Affairs at the time of his departure.

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

Top of the Form

January 9, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HALOZYME THERAPEUTICS, INC.

By: David A. Ramsay

Name: David A. Ramsay Title: Vice President and Chief Financial Officer